Economic Evaluation of Treatment of Macular Edema Due to Central or Hemiretinal Vein Occlusion in the SCORE 2 Trial
Year of Publication
Kymes, Steven Scott, Ingrid U; Oden, Neal; VanVeldhuisen, Paul C; VanVeldhuisen, Paul C
Association for Research in Vision and Ophthalmology Annual Meeting
SCORE2 demonstrated that, for visual acuity letter score (VALS) change, bevacizumab is non-inferior to aflibercept for treatment of macular edema due to central (CRVO) or hemi-retinal vein occlusion (HRVO). While bevacizumab was non-inferior, aflibercept had a numerical advantage in VALS letters gained. The average cost for aflibercept is 10 times that of bevacizumab, but it is not known whether the increased VALS gained offsets this cost.